Kura Oncology, Inc. (KURA) Discusses KO-7246 Data and Development Strategy for Menin Inhibitors in Diabetes Transcript
…
7,270$
6,91%
Echtzeit-Aktienkurs Kura Oncology Inc.
Bid:
Ask:
Nachrichten zur Kura Oncology Inc. Aktie
Kura Oncology: Insiderkäufe und Pipeline-Ausbau als Katalysator für das 30-Dollar-Kursziel von JPMorgan
Kura Oncology (KURA) vollzieht den strategischen Wandel zum kommerziellen Krebs-Therapeutik-Anbieter. JPMorgan sieht bei einem Kursziel von 30 USD ein Umsatzpotenzial…
Kura Oncology, Inc. (KURA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
…
Kura Oncology appoints Jennifer Fulk as CFO
…
Kura Oncology (KURA) Upgraded to Buy: What Does It Mean for the Stock?
Kura Oncology (KURA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the companys earnings prospects.…
Kura Oncology (KURA) im Pivotal-Point-Check: 1,24 Mio. USD CEO-Insider-Kauf löst Kurssprung bei US-Krebsspezialist aus!
Klares Vertrauenssignal: CEO Troy Wilson kauft eigene Aktien für 1,24 Mio. USD. Krebsmedikament auf der Überholspur: Komzifti verzeichnet im…
Stocks making the biggest moves midday: Dicks Sporting Goods, Marvell, AMD, Kura Oncology & more
These are the stocks posting the largest moves midday.…
Stocks making the biggest moves premarket: Dicks Sporting Goods, Advanced Micro Devices, Kura Oncology & more
These are the stocks posting the largest moves in early trading.…
Kura Oncology stock rises on CEO insider purchase
Kura Oncology stock rises on CEO insider purchase…
Kura Oncology, Inc. (KURA) Discusses Long-Term Results of Ziftomenib Combination Therapies in Newly Diagnosed and Relapsed/Refractory AML Transcript
…
Kura Oncology, Inc. (KURA) Discusses Clinical Data and Updated Development Strategy for Darlifarnib - Slideshow
…
Cantor Fitzgerald reiterates Kura Oncology stock Overweight rating
Cantor Fitzgerald reiterates Kura Oncology stock Overweight rating…
Kura Oncology, Inc. (KURA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
…
Kura Oncology, Inc. (KURA) Q1 2026 Earnings Call Transcript
…
Kura Oncology (KURA) Reports Q1 Loss, Tops Revenue Estimates
Kura Oncology (KURA) delivered earnings and revenue surprises of +5.33% and +21.30%, respectively, for the quarter ended March 2026. Do…
Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress
– Oral presentation to feature 99-patient dataset with extended follow-up in newly diagnosed NPM1-m or KMT2A-r AML –…
Kura Oncology, Inc. (KURA) Discusses Updated Data on Darlifarnib and Cabozantinib Combination in Advanced Renal Cell Carcinoma Transcript
…
Kura Oncology shares jump on positive kidney cancer trial data
Kura Oncology shares jump on positive kidney cancer trial data…
Kura Oncology, Inc. 2025 Q4 - Results - Earnings Call Presentation
…
Kura Oncology to Report Fourth Quarter and Full Year 2025 Financial Results
SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to…
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company…
Kura Oncology: H.C. Wainwright bestätigt Kaufempfehlung - Aufnahme von Komfiziti in National Comprehensive Cancer Network Guidelines wird gelobt
Kura Oncology Inc. (KURA) ist ein Biotechnologieunternehmen, welches sich sich auf die Entwicklung präzisionsmedizinischer Therapien zur Krebsbehandlung konzentriert. Der Fokus…
Kura Oncology stock rises after promising cancer drug combination data By Investing.com
Kura Oncology stock rises after promising cancer drug combination data…
Kura Oncology, Inc. (KURA) Discusses Clinical Updates on Farnesyl Transferase Inhibitor Programs and Combination Therapies in Oncology Transcript
…
Kura Oncology at ESMO Congress 2025: Promising Cancer Therapies By Investing.com
Kura Oncology at ESMO Congress 2025: Promising Cancer Therapies…
Kura Oncology, Inc. (KURA) Presents at UBS Virtual Oncology Day Transcript
…
Kura Oncology and Kyowa Kirin Launch Clinical Trial Evaluating Dual Inhibition of NPM1 and FLT3 Mutations in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
– Expanding clinical experience and safety profile of ziftomenib support its evaluation in combination with approved FLT3 inhibitors in frontline AML…
Kura Oncology (KURA) Reports Q2 Loss, Lags Revenue Estimates
Kura Oncology (KURA) delivered earnings and revenue surprises of -600.00% and -89.23%, respectively, for the quarter ended June 2025. Do…
Kura Oncology to Report Second Quarter 2025 Financial Results
SAN DIEGO, July 31, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed…
KURA Stock Rises More Than 15% This Past Week: Heres Why
Kura Oncology shares rise this week after the FDA accepts its NDA for ziftomenib, a potential first-in-class treatment for NPM1-mutant…
Kura Oncology, Inc. 2024 Q4 - Results - Earnings Call Presentation
…
Kura Oncology (KURA) Reports Q4 Loss, Lags Revenue Estimates
Kura Oncology (KURA) delivered earnings and revenue surprises of 65.08% and 76.49%, respectively, for the quarter ended December 2024. Do…
Kura Oncology Inc. (KURA): H.C. Wainwright sieht 379 % Kurspotenzial und verweist auf die Studienfortschritte!
Kura Oncology Inc. (KURA) ist ein Biotech, welcher sich auf die Entwicklung von Präzisionsmedikamenten zur Behandlung von Krebs spezialisiert hat.…
Kura Oncology tumbles as Kyowa collaboration seen hitting M&A prospects By Investing.com
Kura Oncology tumbles as Kyowa collaboration seen hitting M&A prospects…
Kura Oncology, Inc. (KURA) Q3 2024 Earnings Call Transcript
…
Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting
– Ziftomenib combined with 7+3 in 1L NPM1-m or KMT2A-r adverse risk AML patients selected for oral presentation on Saturday,…
Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology
SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed…
Kura Oncology Appoints Michael Vasconcelles, M.D., to Board of Directors
SAN DIEGO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed…
Kura Oncology, Inc. (KURA) Q2 2024 Earnings Call Transcript
…
Kura Oncology to Participate in Jefferies Global Healthcare Conference
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed…
Kura Oncology executive sells over $57k in company stock By Investing.com
Kura Oncology executive sells over $57k in company stock…
Kura Oncology to Participate in Bank of America Securities Healthcare Conference
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed…
Kura Oncology, Inc. (KURA) Q1 2024 Earnings Call Transcript
…
Kura Oncology to Report First Quarter 2024 Financial Results
SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed…
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, April 05, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical…
Earnings call: Kura Oncology reports promising trial results, financial outlook By Investing.com
Earnings call: Kura Oncology reports promising trial results, financial outlook…
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, March 01, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical…
Kura Oncology, Inc. (KURA) Q4 2023 Earnings Call Transcript
…